Clinical trials: Non Small Cell Lung Cancer Stage III
- Condition Non Small Cell Lung Cancer Stage III
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Neoplasms
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.
- Trial name
- NCT02588612
- Testing
- letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
- Trial name
- NCT00883779
- Testing
- Platinum chemotherapy (cisplatin or carboplatin), erlotinib [Tarceva], gemcitabine
- Where
- 26 sites in China, Hong Kong and 5 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Neoplasms,, Metastatic Cancer,
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
The objective of this study will be to investigate the safety and tolerability of AZD6244 given monotherapy or in combination with docetaxel as 2nd line therapy in Japanese patients with Advanced Solid Malignancies or Locally…
- Conditions
- Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, Advanced Solid Malignancies
- Trial name
- NCT01605916
- Testing
- AZD6244
- Where
- 3 sites in Japan
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
In the China extension study, Chinese participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or…
- Trial name
- NCT03850444
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Volunteers
- 262 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer, Anemia
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC).
- Conditions
- Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
- Trial name
- NCT00858364
- Testing
- Darbepoetin alfa
- Where
- 566 sites in United States, Argentina and 35 more
- Volunteers
- 2,549 people
- Sponsor
- Amgen
Non-Small-Cell Lung
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based…
- Trial name
- NCT03456063
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Nab-paclitaxel, Pemetrexed
- Where
- 117 sites in United States, Australia and 22 more
- Volunteers
- 453 people
- Sponsor
- Hoffmann-La Roche
Non-Small-Cell Lung Carcinoma
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
This is a Japan Extension Study of Global Study MK-3475-189 (NCT02578680). This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy…
- Trial name
- NCT03950674
- Testing
- Pembrolizumab 200 mg, Cisplatin, Carboplatin
- Where
- 10 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the…
- Trial name
- FLAURA2 (NCT04035486)
- Testing
- Osimertinib, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin
- Where
- 153 sites in United States, Argentina and 19 more
- Volunteers
- 587 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
The primary purpose of the study was to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib.
- Trial name
- NCT01828112
- Testing
- Ceritinib, Pemetrexed, Docetaxel
- Where
- 97 sites in United States, Belgium and 18 more
- Volunteers
- 231 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer.
- Trial name
- NCT00762034
- Testing
- Pemetrexed, Paclitaxel, Carboplatin
- Where
- 67 sites in United States
- Volunteers
- 939 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
This is a study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab (MK-3475, KEYTRUDA®) in adults with first line metastatic squamous non-small cell lung cancer…
- Trial name
- NCT02775435
- Testing
- Pembrolizumab, Paclitaxel, Nab-paclitaxel
- Volunteers
- 559 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study will evaluate the pharmacokinetics, safety, and efficacy of atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV) in participants with locally advanced or metastatic Non-Small Cell Lung Cancer…
- Trial name
- NCT03735121
- Testing
- Atezolizumab, rHuPH20
- Where
- 74 sites in Argentina, Brazil and 21 more
- Volunteers
- 438 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who are deemed to be ineligible for chemotherapy per…
- Trial name
- DUART (NCT04249362)
- Testing
- Durvalumab
- Where
- 35 sites in United States, France and 4 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of Asian subjects with unresectable stage III non-small cell lung…
- Trial name
- INSPIRE (NCT01015443)
- Testing
- Tecemotide, Single low dose cyclophosphamide, Saline
- Where
- 47 sites in China, Hong Kong and 3 more
- Volunteers
- 285 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
This is a phase I/II study in Japan to evaluate the safety of EMD531444 and its effects on survival time in patients with stage III unresectable non-small cell lung cancer.
- Trial name
- NCT00960115
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Saline
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lung Cancer, Non-Small Cell Lung Cancer
Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this trial is: - To characterize the safety profile of motesanib when used in combination with carboplatin/paclitaxel (CP), with panitumumab or with CP and panitumumab in patients with advanced non-small cell lung…
- Trial name
- NCT00094835
- Testing
- Panitumumab, Motesanib diphosphate, Paclitaxel
- Volunteers
- 51 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase 1/2 multi-center open-label study of BGB324 (bemcentinib) as a single agent (Run-in Cohort) and in combination with erlotinib (Arms A, B, and C) in participants with Stage IIIb or Stage IV non-small cell lung cancer…
- Trial name
- NCT02424617
- Testing
- Erlotinib, Bemcentinib
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- BerGenBio ASA
Small Cell Lung Cancer
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed…
- Trial name
- ADRIATIC (NCT03703297)
- Testing
- Durvalumab, Tremelimumab
- Where
- 183 sites in United States, Argentina and 17 more
- Volunteers
- 730 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.
- Trial name
- NCT00423449
- Testing
- vorinostat, Gemcitabine, Platinum-based agent
- Volunteers
- 61 people
- Sponsor
- Merck Sharp & Dohme LLC